Solid phase synthesis of thymosin beta 9.
Chandramouli. N N; Bhargava. K K KK; Incefy. G S GS; Modak. M J MJ; Merrifield. R B RB
Key Findings
- A solid‑phase method was used to synthesize thymosin beta‑9 with a modified low‑HF deprotection step
- The peptide was purified in one step, achieving a 32% overall yield
- In vitro, thymosin beta‑9 was more active than calf thymus fraction 5 and similar to thymosin beta‑4, but showed no activity in the rosette inhibition assay
Practical Outcomes
- For biohackers, this study offers no actionable protocol, dosage, or safety information. It’s mainly of interest to chemists who need to produce the peptide, not to those looking to supplement or experiment with it.
Summary
The paper describes a lab technique for making a peptide called thymosin beta‑9, showing how they built it on a solid support, got a 32% yield, and tested its activity in a couple of lab assays. It doesn’t give any guidance on how to use the peptide in humans, dosing, safety, or benefits, so it isn’t directly useful for DIY health experiments.
Abstract
Thymosin beta 9, a 41 residue thymic polypeptide, has been synthesized by a solid phase method. A modification of the low HF method was used to deprotect and cleave the peptide from the resin. Thymosin beta 9 was then obtained in analytically pure form by a one-step purification procedure in 32% yield. The activity of thymosin beta 9 in the terminal deoxynucleotidyl transferase assay was greater than calf thymus fraction 5, but comparable to thymosin beta 4. In contrast to thymosin alpha 1, neither beta 4 nor beta 9 was active in the rosette inhibition assay.
Study Information
pubmed
1986
10.1111/j.1399-3011.1986.tb03289.x